KBL Merger Corp. IV SPAC Announces Non-Binding Term Sheet to Acquire CannBioRx Life Sciences Corp. and its Three Interactive Programs

Programs Focused on Developing Novel Pharmaceutical Drugs and Man-Made.

New York, N.Y (May 14, 2019) DOWNLOAD PDF

Katexco Pharmaceuticals Co-founder, Director and Chairman Presents New Multiple Sclerosis Research at 2018 Feinstein Institute Marsh Lecture.

Professor Lawrence Steinman Discusses the Role that Amyloid Proteins Play in Slowing Immune Response in M.S. Patients.

Toronto, Canada (November 5, 2018) DOWNLOAD PDF

Stanford Medical Pioneers Form Katexco Pharmaceuticals to Develop Innovative CBD Therapies to Treat Inflammatory Diseases

Katexco Developing First Drug to Exploit Brain Receptor to Treat Crohn’s Disease, Rheumatoid Arthritis, Multiple Sclerosis and More.

Toronto, Canada (October 24, 2018) DOWNLOAD PDF